Back to Results

Phathom Pharmaceuticals Inc (PHAT)

Featured in High-Beta Stocks Small-Cap Stocks

Phathom Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing treatments for gastrointestinal diseases in the United States. Its lead program includes VOQUEZNA, which has completed Phase III clinical trials for erosive gastroesophageal reflux disease (GERD) and related heartburn in adults. The company is also advancing VOQUEZNA Triple Pak and VOQUEZNA Dual Pak, both of which have completed Phase III clinical trials for Helicobacter pylori treatment. Additional development efforts include VOQUEZNA and vonoprazan for heartburn associated with non-erosive GERD and eosinophilic esophagitis in adults and adolescents. Founded in 2018, Phathom Pharmaceuticals is headquartered in Florham Park, New Jersey.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Technical Outlook FAQ

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Upcoming Dividend Ex-Date Dividend Payment Date Upcoming Dividend Dividend Yield Next Earnings Date P/E Ratio Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Payout Ratio Free Cash Flow / Net Income
NASDAQ-PHAT
$11.74
8.5% Upside
Fair
$23.70
119.0% Upside
Bargain
Fair
—
—
—
0.0%
August 6, 2026
-5.5x
-2.6x
4.2x
845.9 M
1.234 B
39.3%
75.6%
-5.9
—
62.2%
Send a message
Valuation • Fair Value

Phathom Pharmaceuticals Inc (NASDAQ-PHAT) Fair Value by Valuation Model

Compare the primary fair value estimate for Phathom Pharmaceuticals Inc (NASDAQ-PHAT) with model-based valuation references such as DCF, Ben Graham, DDM, EPV and comparable-company valuation.

Primary Valuation Read

Fair Value

$11.74

Estimated upside of 8.5% versus the current market price.

Fair Value Confidence

Med

Confidence level for the primary fair value estimate.

DCF Fair Value

$17.18

Discounted cash flow valuation reference.

Ben Graham Formula Value

$0

Classic Ben Graham valuation formula reference.

DDM Fair Value

NM

Dividend discount model valuation reference.

EPV Fair Value

$13.91

Earnings power value estimate.

Comps Fair Value

$9.57

Comparable-company valuation reference.

Analyst Price Target

$23.70

Analysts imply upside of 119.0%.

How to read these valuation models

Use this section to compare the primary fair value estimate for Phathom Pharmaceuticals Inc (NASDAQ-PHAT) with several model-based valuation references. Different models can produce different outputs because each method relies on a different set of assumptions, so the primary fair value estimate should be read alongside the model spread rather than in isolation.

Profitability • Growth

Profitability & Growth for Phathom Pharmaceuticals Inc (NASDAQ-PHAT)

A compact read on revenue, forward revenue expectations, EBITDA and operating profitability trends.

Revenue

204.9 M

Current operating scale indicator.

Revenue Forecast

333.7 M

Forward revenue estimate.

EBITDA

-96.034 M

Current operating profitability reference.

EBITDA Forecast

18.486 M

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review Phathom Pharmaceuticals Inc (NASDAQ-PHAT) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Phathom Pharmaceuticals Inc (NASDAQ-PHAT)

Review financial health, earnings quality and balance-sheet risk through Piotroski, Beneish, Altman and cash conversion metrics.

Financial Health

Fair

Mixed or neutral financial-health read.

Piotroski Score

4

Mid-range quality score.

Beneish M-Score

-1.95

Intermediate zone that deserves monitoring.

Altman Z-Score

-5.9

Lower score that deserves closer risk review.

FCF / Net Income

62.2%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Phathom Pharmaceuticals Inc (NASDAQ-PHAT). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Phathom Pharmaceuticals Inc (NASDAQ-PHAT)

Track the next earnings date, ex-dividend date, dividend payment date, dividend yield and upcoming distribution details where available.

Next Earnings Date

August 6, 2026

Days to Earnings

16

Dividend Payment Date

Not available

Ex-Dividend Date

Not available

Dividend Yield

0.0%

Income yield reference.

Upcoming Dividend

Not available

Data is currently unavailable.

Payment Type

Not available

Data is currently unavailable.

Dividend Currency

Not available

Data is currently unavailable.

Payout Ratio

Not available

Data is currently unavailable.

How to read events and dividends

This section helps investors track time-sensitive items for Phathom Pharmaceuticals Inc (NASDAQ-PHAT), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

Phathom Pharmaceuticals Inc (NASDAQ-PHAT) Stock Forecast & Technical Outlook

Review Phathom Pharmaceuticals Inc (NASDAQ-PHAT) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Buy

The 15-minute technical read for Phathom Pharmaceuticals Inc (NASDAQ-PHAT) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Neutral

The 1-hour technical read for Phathom Pharmaceuticals Inc (NASDAQ-PHAT) is currently Neutral. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Sell

The daily technical read for Phathom Pharmaceuticals Inc (NASDAQ-PHAT) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Sell

The weekly technical read for Phathom Pharmaceuticals Inc (NASDAQ-PHAT) is currently Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Neutral

The monthly technical read for Phathom Pharmaceuticals Inc (NASDAQ-PHAT) is currently Neutral. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Phathom Pharmaceuticals Inc (NASDAQ-PHAT)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Strong Buy

Based on the available recommendation mix, Phathom Pharmaceuticals Inc (NASDAQ-PHAT) has a Strong Buy consensus, with 7 buy, 1 hold and 0 sell recommendations in the current data set.

Buy 7
Hold 1
Sell 0
FAQ • Fast Investor Answers

Phathom Pharmaceuticals Inc (NASDAQ-PHAT) Stock FAQ

Quick answers about Phathom Pharmaceuticals Inc (NASDAQ-PHAT) stock, including fair value, valuation rating, analyst price target, dividends, earnings dates, market capitalization, financial health and other key stock analysis metrics.

Fair Value
$11.74
Estimated upside 8.5%
Valuation Rating
Undervalued
Estimated upside of 8.5%
Analyst Target
$23.70
Implied upside 119.0%
Financial Health
Fair
Current financial-health read

The current fair value estimate for Phathom Pharmaceuticals Inc (NASDAQ-PHAT) is $11.74. This implies an estimated upside of 8.5% versus the current market price.

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 8.5% versus the current market price.

The available analyst price target for Phathom Pharmaceuticals Inc (NASDAQ-PHAT) is $23.70. The analyst target implies estimated upside of 119.0%.

The current financial health read for Phathom Pharmaceuticals Inc (NASDAQ-PHAT) is Fair. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Phathom Pharmaceuticals Inc (NASDAQ-PHAT) is August 6, 2026.

Based on the current data, dividend yield is 0.0%.

The current P/E ratio listed for Phathom Pharmaceuticals Inc (NASDAQ-PHAT) is -5.5x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

The current market capitalization listed for Phathom Pharmaceuticals Inc is 845.9 M.

The current enterprise value listed for Phathom Pharmaceuticals Inc is 1.234 B. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Phathom Pharmaceuticals Inc is NASDAQ-PHAT, and the stock is listed on NASDAQ.

Phathom Pharmaceuticals Inc (NASDAQ-PHAT) is listed on NASDAQ.

The current debt-to-total-capital ratio listed for Phathom Pharmaceuticals Inc is 39.3%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Phathom Pharmaceuticals Inc is 75.6%. Free float helps investors understand how much of the share base is available for public trading.

Similar Pharmaceuticals Stocks on NASDAQ View more

AstraZeneca PLC ADR (AZN) AstraZeneca PLC ADR (AZN)
Sanofi ADR (SNY) Sanofi ADR (SNY)
Royalty Pharma Plc (RPRX) Royalty Pharma Plc (RPRX)
Viatris Inc (VTRS) Viatris Inc (VTRS)
Jazz Pharmaceuticals PLC (JAZZ) Jazz Pharmaceuticals PLC (JAZZ)
Axsome Therapeutics Inc (AXSM) Axsome Therapeutics Inc (AXSM)
Corcept Therapeutics Incorporated (CORT) Corcept Therapeutics Incorporated (CORT)
Crinetics Pharmaceuticals Inc (CRNX) Crinetics Pharmaceuticals Inc (CRNX)
Liquidia Technologies Inc (LQDA) Liquidia Technologies Inc (LQDA)
Belite Bio Inc ADR (BLTE) Belite Bio Inc ADR (BLTE)
Ligand Pharmaceuticals Incorporated (LGND) Ligand Pharmaceuticals Incorporated (LGND)
Definium Therapeutics Inc (DFTX) Definium Therapeutics Inc (DFTX)
Amneal Pharmaceuticals Inc Class A (AMRX) Amneal Pharmaceuticals Inc Class A (AMRX)
Indivior PLC (INDV) Indivior PLC (INDV)
Edgewise Therapeutics Inc (EWTX) Edgewise Therapeutics Inc (EWTX)
Enliven Therapeutics Inc (ELVN) Enliven Therapeutics Inc (ELVN)
Alumis Inc (ALMS) Alumis Inc (ALMS)
Structure Therapeutics Inc ADR (GPCR) Structure Therapeutics Inc ADR (GPCR)
MBX Biosciences Inc (MBX) MBX Biosciences Inc (MBX)
Supernus Pharmaceuticals Inc (SUPN) Supernus Pharmaceuticals Inc (SUPN)
ATAI Beckley Inc (ATAI) ATAI Beckley Inc (ATAI)
Regencell Bioscience Holdings Ltd (RGC) Regencell Bioscience Holdings Ltd (RGC)
Tarsus Pharmaceuticals Inc (TARS) Tarsus Pharmaceuticals Inc (TARS)
Trevi Therapeutics Inc (TRVI) Trevi Therapeutics Inc (TRVI)